S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Forecast, Price & News

$1.11
-0.02 (-1.77%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.10
▼
$1.15
50-Day Range
N/A
52-Week Range
$1.02
▼
$1.58
Volume
767,157 shs
Average Volume
507,057 shs
Market Capitalization
$194.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesOptions ChainShort InterestSocial Media

Lineage Cell Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
440.5% Upside
$6.00 Price Target
Short Interest
Bearish
3.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.15) to ($0.17) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

See Top Rated MarketRank™ Stocks Here

LCTX stock logo

About Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LCTX Price History

LCTX Stock News Headlines

September 19, 2023 | finance.yahoo.com
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
September 13, 2023 | finance.yahoo.com
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 11, 2023 | finance.yahoo.com
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
September 6, 2023 | finance.yahoo.com
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
September 6, 2023 | benzinga.com
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
September 1, 2023 | markets.businessinsider.com
Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)
August 29, 2023 | finance.yahoo.com
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
August 15, 2023 | markets.businessinsider.com
Maxim Group Remains a Buy on Lineage Therap (LCTX)
August 13, 2023 | finance.yahoo.com
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call Transcript
August 11, 2023 | finance.yahoo.com
Q2 2023 Lineage Cell Therapeutics Inc Earnings Call
August 11, 2023 | investing.com
Lineage Cell Therapeutics (LCTX) Earnings Dates & Reports
August 10, 2023 | finance.yahoo.com
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
August 10, 2023 | finance.yahoo.com
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023 | benzinga.com
Lineage Cell Therapeutics Earnings Preview
August 8, 2023 | finance.yahoo.com
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
August 3, 2023 | thestreet.com
Lineage Cell Therapeutics, Inc.
August 3, 2023 | finance.yahoo.com
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
July 26, 2023 | markets.businessinsider.com
Maxim Group Sticks to Their Buy Rating for Lineage Therap (LCTX)
July 24, 2023 | msn.com
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
July 24, 2023 | finance.yahoo.com
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
July 19, 2023 | finance.yahoo.com
LCTX - Lineage Cell Therapeutics, Inc.
July 12, 2023 | fool.com
Lineage Cell Therapeutics (NYSEMKT: LCTX)
July 7, 2023 | markets.businessinsider.com
B.Riley Financial Keeps Their Buy Rating on Lineage Therap (LCTX)
May 22, 2023 | finance.yahoo.com
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
May 16, 2023 | finance.yahoo.com
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript
See More Headlines
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LCTX Company Calendar

Last Earnings
8/10/2023
Today
10/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:LCTX
CUSIP
N/A
CIK
N/A
Web
www.lineagecell.com
Phone
(442) 287-8963
Fax
510-521-3389
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+440.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,270,000.00
Net Margins
-209.27%
Pretax Margin
-221.85%
Return on Equity
-30.40%
Return on Assets
-18.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.02
Quick Ratio
3.02

Sales & Book Value

Annual Sales
$14.70 million
Price / Sales
13.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.42 per share
Price / Book
2.64

Miscellaneous

Outstanding Shares
174,990,000
Free Float
125,816,000
Market Cap
$194.24 million
Optionable
Optionable
Beta
1.67
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Brian M. Culley M.A. (Age 52)
    M.B.A., CEO, Pres & Director
    Comp: $944.15k
  • Ms. Jill Ann Howe (Age 47)
    CFO & Principal Financial and Accounting Officer
    Comp: $125.52k
  • Mr. George A. Samuel III (Age 42)
    J.D., Gen. Counsel & Company Sec.
    Comp: $560.95k
  • Ioana C. Hone
    Director of Investor Relations
  • Dr. Gary S. Hogge D.V.M. (Age 54)
    Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs
  • Ms. Brandi L. Roberts CPA (Age 49)
    M.B.A., Consultant
  • Mr. William Annett MBA (Age 69)
    Pres & CEO of OncoCyte Corp.
  • Ms. Alexandra Hernandez
    Sr. Director of Fin. & Controller
  • Dr. Harold D. Waitz (Age 81)
    VP of Regulatory Affairs & Quality Control

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













LCTX Stock - Frequently Asked Questions

Should I buy or sell Lineage Cell Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LCTX shares.
View LCTX analyst ratings or view top-rated stocks.

What is Lineage Cell Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1-year target prices for Lineage Cell Therapeutics' stock. Their LCTX share price forecasts range from $5.00 to $7.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 440.5% from the stock's current price.
View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts.

How have LCTX shares performed in 2023?

Lineage Cell Therapeutics' stock was trading at $1.46 at the beginning of 2023. Since then, LCTX shares have decreased by 24.0% and is now trading at $1.11.
View the best growth stocks for 2023 here.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company had revenue of $3.23 million for the quarter, compared to analyst estimates of $2.65 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 30.40% and a negative net margin of 209.27%.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lineage Cell Therapeutics' stock price today?

One share of LCTX stock can currently be purchased for approximately $1.11.

How much money does Lineage Cell Therapeutics make?

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has a market capitalization of $194.24 million and generates $14.70 million in revenue each year. The company earns $-26,270,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How can I contact Lineage Cell Therapeutics?

Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The official website for the company is www.lineagecell.com. The company can be reached via phone at (442) 287-8963, via email at ir@lineagecell.com, or via fax at 510-521-3389.

This page (NYSEAMERICAN:LCTX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -